neprilysin; ARNI; angiotensin; type 2 diabetes; heart failure
Abstract :
[en] Sacubitril/valsartan, a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI), is indicated for the treatment of heart failure with reduced ejection fraction. It has demonstrated benefits in terms of
cardiovascular morbidity and mortality reduction in this population. Recently, this drug association has also been shown to improve glycemic control and insulin sensitivity in patients with obesity and/or type 2 diabetes. Furthermore, some studies suggest a protective role of this new drug class in diabetic nephropathy. Altogether, these data raise the question about the potential place of ARNI in prevention and treatment of type 2 diabetes, a condition closely associated with heart failure. [fr] Le sacubitril/valsartan, premier médicament de la classe des ARNI (Angiotensin Receptor-Neprilysin Inhibitor), est indiqué dans le traitement de l’insuffisance cardiaque à fraction d’éjection réduite. Il a démontré des bénéfices en termes de réduction de morbimortalité cardiovasculaire dans cette population. Récemment, il a également été rapporté que cette association thérapeutique améliore le contrôle glycémique et la sensibilité à l’insuline des patients avec une obésité et/ou un diabète de type 2. De plus, certaines études suggèrent également un rôle protecteur de cette nouvelle classe médicamenteuse dans la néphropathie diabétique. Ces données soulèvent la question de
la place éventuelle des ARNI dans la prévention et le traitement du diabète de type 2, une pathologie étroitement associée à l’insuffisance cardiaque.
Esser, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de diabétologie, nutrition, maladies métaboliques
PAQUOT, Nicolas ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de diabétologie, nutrition, maladies métaboliques
Language :
French
Title :
Intérêt de la combinaison sacubitril/valsartan dans le diabète de type 2
Alternative titles :
[en] Potential role of sacubitril/valsartan combination in type 2 diabetes
Kristensen SL, Preiss D, Jhund PS, et al. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure with Reduced Ejection Fraction: Insights from Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail 2016; 9:e002560.
De Flines J, Scheen AJ. Diabète sucré et décompensation cardiaque : Spécificités éthiopathogéniques et thérapeutiques. Rev Med Suisse 2006; 2:1893-6, 1898-900.
Scheen AJ, Lancellotti P. Inhibiteurs des SGLT2 : nouvelle option pour prévenir ou traiter l insuffisance cardiaque. Rev Med Liege 2021; 76:248-55.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC)Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37:2129-200.
Roques BP, Noble F, Dauge V, Fournié-Zaluski MC, Beaumont A. Neutral Endopeptidase 24.11: Structure, Inhibition, and Experimental and Clinical Pharmacology. Pharmacol Rev 1993; 45:87-146.
McMurray JJV, Packer M, Desai AS, et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med 2014; 371:993-1004.
Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med 2019; 380:539-48.
Yoshimura M, Yasue H, Ogawa H. Pathophysiological Significance and Clinical Application of ANP and BNP in Patients with Heart Failure. Can J Physiol Pharmacol 2001; 79:730-5.
Greene SJ, Gheorghiade M, Borlaug BA, et al. The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure with Preserved Ejection Fraction. J Am Heart Assoc 2013; 2:e000536.
Januzzi JL Jr, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment with Cardiac Structure and Function in Patients with Heart Failure with Reduced Ejection Fraction. JAMA 2019; 322:1085-95.
Vardeny O, Miller R, Solomon SD. Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure. JACC Heart Fail 2014; 2:663-70.
Khan MS, Felker GM, Piña IL, et al. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients with Heart Failure with and without Diabetes. JACC Heart Fail 2021; 9:137-45.
Antol DD, Casebeer AW, DeClue RW, Stemkowski S, Russo PA. An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction. Adv Ther 2018; 35:785-95.
Khariton Y, Fonarow GC, Arnold SV, et al. Association between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure with Reduced Ejection Fraction. JACC Heart Fail 2019; 7:933-41.
Esser N, Zraika S. Neprilysin Inhibition: A New Therapeutic Option for Type 2 Diabetes? Diabetologia 2019; 62:1113-22.
Rice GI, Jones AL, Grant PJ, et al. Circulating Activities of Angiotensin-Converting Enzyme, Its Homolog, Angiotensin-Converting Enzyme 2, and Neprilysin in a Family Study. Hypertension 2006; 48:914-20.
Standeven KF, Hess K, Carter AM, et al. Neprilysin, Obesity and the Metabolic Syndrome. Int J Obes (Lond) 2011; 35:1031-40.
Willard JR, Barrow BM, Zraika S. Improved Glycaemia in High-Fat-Fed Neprilysin-Deficient Mice Is Associated with Reduced DPP-4 Activity and Increased Active GLP-1 Levels. Diabetologia 2017; 60:701-8.
Zraika S, Koh DS, Barrow BM, et al. Neprilysin Deficiency Protects against Fat-Induced Insulin Secretory Dysfunction by Maintaining Calcium Influx. Diabetes 2013; 62:1593-601.
Chipkin RE, Kreutner W, Billard W. Potentiation of the Hypoglycemic Effect of Insulin by Thiorphan, an Enkephalinase Inhibitor. Eur J Pharmacol 1984; 102:151-4.
Arbin V, Claperon N, Fournié-Zaluski MC, Roques BP, Peyroux J. Acute Effect of the Dual Angiotensin-Converting Enzyme and Neutral Endopeptidase 24-11 Inhibitor Mixanpril on Insulin Sensitivity in Obese Zucker Rat. Br J Pharmacol 2001; 133:495-502.
Wang CH, Leung N, Lapointe N, et al. Vasopeptidase Inhibitor Omapatrilat Induces Profound Insulin Sensitization and Increases Myocardial Glucose Uptake in Zucker Fatty Rats: Studies Comparing a Vasopeptidase Inhibitor, Angiotensin-Converting Enzyme Inhibitor, and Angiotensin II Type I Receptor Blocker. Circulation 2003; 107:1923-9.
Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral Endopeptidase 24.11 and Dipeptidyl Peptidase IV Are Both Mediators of the Degradation of Glucagon-Like Peptide 1 in the Anaesthetised Pig. Diabetologia 2005; 48:1882-90.
Wu HT, Chang CK, Cheng KC, et al. Increase of Plasma Insulin by Racecadotril, an Inhibitor of Enkephalinase, in Wistar Rats. Horm Metab Res 2010; 42:261-7.
Jordan J, Stinkens R, Jax T, et al. Improved Insulin Sensitivity with Angiotensin Receptor Neprilysin Inhibition in Individuals with Obesity and Hypertension. Clin Pharmacol Ther 2017; 101:254-63.
Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of Sacubitril/Valsartan versus Enalapril on Glycaemic Control in Patients with Heart Failure and Diabetes: A Post-Hoc Analysis from the PARADIGM-HF Trial. Lancet Diabetes Endocrinol 2017; 5:333-40.
Nougué H, Pezel T, Picard F, et al. Effects of Sacubitril/Valsartan on Neprilysin Targets and the Metabolism of Natriuretic Peptides in Chronic Heart Failure: A Mechanistic Clinical Study. Eur J Heart Fail 2019; 21:598-605.
Vodovar N, Nougué H, Launay JM, Solal AC, Logeart D. Sacubitril/Valsartan in PARADIGM-HF. Lancet Diabetes Endocrinol 2017; 5:495-6.
Hupe-Sodmann K, McGregor GP, Bridenbaugh R, et al. Characterisation of the Processing by Human Neutral Endopeptidase 24.11 of GLP-1(7-36) Amide and Comparison of the Substrate Specificity of the Enzyme for other Glucagon-Like Peptides. Regul Pept 1995; 58:149-56.
Windeløv JA, Wewer Albrechtsen NJ, Kuhre RE, et al. Why Is It So Difficult to Measure Glucagon-Like Peptide-1 in a Mouse? Diabetologia 2017; 60:2066-75.
Wewer Albrechtsen NJ, Mark PD, Terzic D, et al. Sacubitril/Valsartan Augments Postprandial Plasma Concentrations of Active GLP-1 when Combined with Sitagliptin in Men. J Clin Endocrinol Metab 2019; jc.2019-00515.
Northridge DB, Jardine AG, Alabaster CT, et al. Effects of UK 69 578: A Novel Atriopeptidase Inhibitor. Lancet 1989; 2:591-3.
González W, Soleilhac JM, Fournié-Zaluski MC, Roques BP, Michel JB. Characterization of Neutral Endopeptidase in Vascular Cells, Modulation of Vasoactive Peptide Levels. Eur J Pharmacol 1998; 345:323-31.
Gafford JT, Skidgel RA, Erdös EG, Hersh LB. Human Kidney "Enkephalinase", a Neutral Metalloendopeptidase that Cleaves Active Peptides. Biochemistry 1983; 22:3265-71.
Lisy O, Jougasaki M, Schirger JA, et al. Neutral Endopeptidase Inhibition Potentiates the Natriuretic Actions of Adrenomedullin. Am J Physiol 1998; 275:F410-4.
Kjeldsen SAS, Hansen LH, Esser N, et al. Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice with Potential Effects on Amino Acid Metabolism. J Endocrine Society 2021; bvab084.
Underwood PC, Adler GK. The Renin Angiotensin Aldosterone System and Insulin Resistance in Humans. Curr Hypertens Rep 2013; 15:59-70.
Scheen AJ. Renin-Angiotensin System Inhibition Prevents Type 2 Diabetes Mellitus. Part 1. A Meta-Analysis of Randomised Clinical Trials. Diabetes Metab 2004; 30:487-96.
Van der Zijl NJ, Moors CC, Goossens GH, et al. Valsartan Improves -Cell Function and Insulin Sensitivity in Subjects with Impaired Glucose Metabolism: A Randomized Controlled Trial. Diabetes Care 2011; 34:845-51.
Fogari R, Preti P, Zoppi A, et al. Effect of Valsartan Addition to Amlodipine on Insulin Sensitivity in Overweight-Obese Hypertensive Patients. Intern Med 2008; 47:1851-7.
McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362:1477-90.
Packer M, Claggett B, Lefkowitz MP, et al. Effect of Neprilysin Inhibition on Renal Function in Patients with Type 2 Diabetes and Chronic Heart Failure Who Are Receiving Target Doses of Inhibitors of the Renin-Angiotensin System: A Secondary Analysis of the PARADIGM-HF Trial. Lancet Diabetes Endocrinol 2018; 6:547-54.
Voors AA, Gori M, Liu LCY, et al. Renal Effects of the Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Patients with Heart Failure and Preserved Ejection Fraction. Eur J Heart Fail 2015; 17:510-7.
Hsieh HL, Chen CY, Chen CH, et al. Renal Protective Effect of Sacubitril/Valsartan in Patients with Heart Failure. Sci Rep 2021; 11:4593.
Solomon SD, Jhund PS, Claggett BL, et al. Effect of Dapagliflozin in Patients with HFrEF Treated with Sacubitril/Valsartan: The DAPA-HF Trial. JACC Heart Fail 2020; 8:811-8.
Packer M, Anker SD, Butler J, et al. Influence of Neprilysin Inhibition on the Efficacy and Safety of Empagliflozin in Patients with Chronic Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Eur Heart J 2021; 42:671-80.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.